NCT01702506View on ClinicalTrials.gov

Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

dacomitinib fasted

Overnight fasted subjects will receive a single 45 mg dose of dacomitinib

DRUG

dacomitinib fed

Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal

DRUG

dacomitinib+antacid

Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01702506 - Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804) | Biotech Hunter | Biotech Hunter